Analysis of the AML dataset from The Cancer Genome Atlas (TCGA) revealed that there was no difference in CHAF1B mRNA levels between different subtypes of AML, and higher expression correlates with poor outcome [40]. Here, CHAF1B is linked to acute myeloid leukemia.